据半岛电视台：英国和巴林请求就也门问题召开的联合国安理会会议将于当地时间今晚举行。

CITIC Securities says since early 2026 China's innovative-drug market has seen rapid domestic volume growth. Interim results from leading innovators show fast revenue expansion driven by new products and biopharma firms are moving into a profitability inflection. Overseas programs are entering Phase III/registration-study stages, and several upcoming international conferences create concentrated data catalysts. The firm highlights three investor priorities: (1) leading internationalized innovators poised for global value realization; (2) top domestic innovators entering a new product-ramp growth phase; (3) pipeline assets with global potential whose internationalization may accelerate value realization. CITIC maintains an Outperform rating on the sector.

Reportedly, TSMC is accelerating construction of a 1.4nm fab at the Central Taiwan Science Park. The first P1 plant is expected to begin trial runs in April next year, and volume production is now anticipated in H2 2027, ahead of an earlier 2028 target. Two temporary on-site offices are being installed for April completion, with an initial intake of over 5,400 operations and outsourced staff, sources said.